Drug Profile

RTX 015

Alternative Names: RAY-001; RTX-015

Latest Information Update: 24 Jun 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Ray Therapeutics
Class Eye disorder therapies; Gene therapies
Mechanism of Action Gene transference; Rhodopsin replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase II/III Retinitis pigmentosa
Phase I Choroideraemia
Preclinical Stargardt disease

Most Recent Events

24 Jun 2026 Phase-II/III clinical trials in Retinitis pigmentosa in USA (Intravitreous) prior to June 2026 (Ray therapeutics pipeline, June 2026)
01 Apr 2026 RTX 015 receives Regenerative Medicine Advanced Therapy (RMAT) status for Retinitis pigmentosa in USA
09 Dec 2025 Adverum Biotechnologies has been acquired by Eli Lilly and Company

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com